The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

As a precautionary measure, Lupin Pharmaceuticals, Inc. is initiating a voluntary recall of lot QA01081, expiry: April 2027 of Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg (100's) to the retail level. This lot is being recalled due to a market complaint received from a pharmacist, indicating single foreign tablet mix up, which is distinct in size, color and shape within this batch/bottle.

There are distinct differences in the physical appearance between the foreign tablet (white, oblong tablet) and the Lisinopril and HCTZ tablets (yellow, round tablets) and these differences are visually detectable. Further, the pharmacist did not dispense medication to the patient and the bottle was quarantined.

In this instance, there is no health hazard exists as medication was not dispensed to the patient.

The pill is described as yellow, round tablets, with "LL" debossed on one side and "B02" on other side.

The recalled lot was distributed between December 2024 to January 2025 to the wholesalers/ distributors and drug chain nationwide.

PRODUCT: Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg (100's)

NDC NUMBER: 68180-519-01

LOT NUMBER: QA01081

EXPIRATION DATE: April 2027